1. Scrip
  2. >>Archive

FDA-backed study provides path forward for Probuphine

 
• By Donna Young

Titan Pharmaceuticals and its partner Braeburn Pharmaceuticals on 3 March said they have agreed in principle with the US FDA on the design of a trial to support the resubmission of the new drug application (NDA) for Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate), a subdermal implant under investigation as a maintenance treatment of opioid dependence.

Titan Pharmaceuticals and its partner Braeburn Pharmaceuticals on 3 March said they have agreed in principle with the US FDA on the design of a trial to support the resubmission of the new drug application (NDA) for Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate), a subdermal implant under investigation as a maintenance treatment of opioid dependence.

The FDA had rejected the Probuphine NDA on 1 May 2013 (scripintelligence.com, 1 May 2013).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.